Ketone Dose and Cerebral Blood Flow Study

Last updated: December 1, 2023
Sponsor: McMaster University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Brain Function

Treatment

Placebo

Low Dose β-OHB

High Dose β-OHB

Clinical Study ID

NCT06032156
kCBF
  • Ages 18-35
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Ketone bodies are produced by the liver during periods of food scarcity or severe carbohydrate restriction. Blood ketones are an alternative fuel source used by the brain, heart, and skeletal muscle during periods of fasting. Further, ketones bodies act as a signalling molecule that have pleiotropic effects that upregulate cellular stress-resistance pathways throughout the body.

Oral supplements containing exogenous ketones have recently become available and represent a novel tool for increasing plasma ketone bodies without the need for dietary restriction. Early evidence suggests that oral ketone supplements may enhance cerebral blood flow and improve cognition. However, the dose-dependent effects of a single ketone supplement on cerebral blood flow and cognition in young adults is currently unknown.

The purpose of this study is to characterize the effects of ingesting a high versus low dose of an oral ketone monoester on cerebral blood flow, circulating blood markers, and cognition in young adults.

As an exploratory aim, this study will investigate how oxygen uptake kinetics during submaximal exercise are impacted 2 hours after ingestion of a ketone supplement. Recent findings indicate that ketone supplementation may impair exercise performance due to the physiological stress (i.e., pH disturbances) imposed by an acute ketone dose. Delaying exercise onset by 2 hours after ingestion of a ketone supplement may enhance oxygen kinetics in a dose-dependent manner.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Between the ages of 18 and 35

Exclusion

Exclusion Criteria:

  • Presence of obesity (body mass index > 30 kg/m^2)
  • Presence of known cardiovascular disease
  • Presence of type 2 diabetes
  • History of cardiovascular events requiring hospitalization (i.e., heart attack)
  • History of concussion(s) with persistent symptoms
  • Currently following a ketogenic diet and/or taking ketone body supplements

Study Design

Total Participants: 20
Treatment Group(s): 3
Primary Treatment: Placebo
Phase:
Study Start date:
November 08, 2023
Estimated Completion Date:
August 31, 2024

Connect with a study center

  • McMaster University

    Hamilton, Ontario L8S 4K1
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.